Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PG-102 in Obesity and Type 2 Diabetes
NCT06712615Phase 2Active, not recruiting
- Sponsor
- PROGEN
- Start
- Dec 2024
- Primary completion
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PG-102 in type 2 diabetes mellitus (T2DM) and obesity (6 cohorts), sponsored by PROGEN. Primary endpoints: Change in Glycated Hemoglobin at 14 weeks and Percent Change from Baseline in Body Weight at 14 weeks. Started Dec 2024; status: active, not recruiting.
02
Drugs
PG-102
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06712615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06712615.